NO931840L - Protein-C-derivater - Google Patents

Protein-C-derivater

Info

Publication number
NO931840L
NO931840L NO931840A NO931840A NO931840L NO 931840 L NO931840 L NO 931840L NO 931840 A NO931840 A NO 931840A NO 931840 A NO931840 A NO 931840A NO 931840 L NO931840 L NO 931840L
Authority
NO
Norway
Prior art keywords
derivatives
human protein
protein
producing
high activity
Prior art date
Application number
NO931840A
Other languages
English (en)
Other versions
NO311299B1 (no
NO931840D0 (no
Inventor
Bruce Edwaed Gerlitz
Brian William Grinnell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO931840D0 publication Critical patent/NO931840D0/no
Publication of NO931840L publication Critical patent/NO931840L/no
Publication of NO311299B1 publication Critical patent/NO311299B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO19931840A 1992-05-21 1993-05-19 Protein C derivater, rekombinant DNA molekyl, kodende dette samt fremgangsmåte for fremstilling av proteinene NO311299B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88719192A 1992-05-21 1992-05-21

Publications (3)

Publication Number Publication Date
NO931840D0 NO931840D0 (no) 1993-05-19
NO931840L true NO931840L (no) 1993-11-22
NO311299B1 NO311299B1 (no) 2001-11-12

Family

ID=25390640

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19931840A NO311299B1 (no) 1992-05-21 1993-05-19 Protein C derivater, rekombinant DNA molekyl, kodende dette samt fremgangsmåte for fremstilling av proteinene

Country Status (23)

Country Link
US (1) US5453373A (no)
EP (1) EP0575054B1 (no)
JP (1) JP3564150B2 (no)
KR (1) KR100291529B1 (no)
CN (1) CN1080658A (no)
AT (1) ATE286121T1 (no)
AU (1) AU661901B2 (no)
BR (1) BR9301944A (no)
CA (1) CA2096604C (no)
CZ (1) CZ286016B6 (no)
DE (1) DE69333727T2 (no)
DK (1) DK0575054T3 (no)
ES (1) ES2233925T3 (no)
FI (1) FI932282A (no)
HU (1) HU218408B (no)
IL (1) IL105757A0 (no)
MX (1) MX9302917A (no)
MY (1) MY110664A (no)
NO (1) NO311299B1 (no)
NZ (1) NZ247651A (no)
PH (1) PH29911A (no)
PT (1) PT575054E (no)
RU (1) RU2122004C1 (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067525C (en) * 1991-05-09 1998-09-15 Helmut G. Alt Organometallic fluorenyl compounds, preparation and use
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
AU2870992A (en) * 1991-10-04 1993-05-03 Board Of Regents Of The University Of Nebraska, The A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US6159468A (en) 1997-04-28 2000-12-12 Eli Lilly And Company Activated protein C formulations
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
KR20010013413A (ko) * 1997-06-05 2001-02-26 피터 지. 스트링거 혈전성 질환의 치료 방법
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
AU5131699A (en) * 1998-07-31 2000-02-21 Eli Lilly And Company Cryogranulation of activated protein c
WO2000023101A1 (en) 1998-10-22 2000-04-27 Eli Lilly And Company Methods for treating sepsis
CA2351067A1 (en) 1998-11-13 2000-05-25 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
CN1326356A (zh) 1998-11-20 2001-12-12 伊莱利利公司 治疗病毒性出血热的方法
AU1723200A (en) 1998-11-23 2000-06-13 Eli Lilly And Company Method of treating sickle cell disease and thalassemia
US6998122B1 (en) * 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
AU1751801A (en) * 1999-11-19 2001-05-30 Eli Lilly And Company Protein c derivatives
DE60108076T2 (de) * 2000-02-02 2006-03-16 Eli Lilly And Co., Indianapolis Protein c derivate
US6630138B2 (en) 2000-02-11 2003-10-07 Eli Lilly And Company Protein C derivatives
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2002210388B2 (en) * 2000-10-18 2006-11-23 Perseid Therapeutics Llc Protein C or activated protein C like molecules
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
CN100392079C (zh) * 2000-10-18 2008-06-04 马克西根公司 蛋白c或活化的蛋白c-样分子
WO2002085117A1 (en) * 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
AU2003232176A1 (en) * 2002-06-14 2003-12-31 Maxygen Aps Protein c variants with altered properties
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
US20090148458A1 (en) * 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
WO2007140625A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
ATE520414T1 (de) * 2007-06-18 2011-09-15 Univ Oregon Health & Science Protein c zur verwendung bei der aufrechterhaltung der hämostase
WO2009089620A1 (en) * 2008-01-15 2009-07-23 The Universityof British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
CN104262479A (zh) 2008-12-19 2015-01-07 国家健康与医学研究院 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
WO2015157791A1 (en) 2014-04-16 2015-10-22 The University Of Sydney Treatment of abnormal cutaneous scarring
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c

Also Published As

Publication number Publication date
DK0575054T3 (da) 2005-04-25
NO311299B1 (no) 2001-11-12
FI932282A0 (fi) 1993-05-19
RU2122004C1 (ru) 1998-11-20
FI932282A (fi) 1993-11-22
NZ247651A (en) 1995-03-28
KR930023370A (ko) 1993-12-18
PT575054E (pt) 2005-03-31
JP3564150B2 (ja) 2004-09-08
CN1080658A (zh) 1994-01-12
HU218408B (hu) 2000-08-28
US5453373A (en) 1995-09-26
DE69333727D1 (de) 2005-02-03
NO931840D0 (no) 1993-05-19
CA2096604A1 (en) 1993-11-22
BR9301944A (pt) 1993-11-30
PH29911A (en) 1996-09-16
EP0575054B1 (en) 2004-12-29
KR100291529B1 (ko) 2001-06-01
EP0575054A2 (en) 1993-12-22
IL105757A0 (en) 1993-09-22
MY110664A (en) 1999-01-30
ES2233925T3 (es) 2005-06-16
AU3869993A (en) 1993-11-25
ATE286121T1 (de) 2005-01-15
CZ94893A3 (en) 1994-01-19
CZ286016B6 (cs) 1999-12-15
DE69333727T2 (de) 2005-12-15
HU9301461D0 (en) 1993-09-28
HUT69615A (en) 1995-09-28
JPH0680698A (ja) 1994-03-22
AU661901B2 (en) 1995-08-10
CA2096604C (en) 2003-12-16
MX9302917A (es) 1993-11-01
EP0575054A3 (en) 1995-04-19

Similar Documents

Publication Publication Date Title
FI932282A (fi) Protein c-derivat
NO900770D0 (no) Produksjon av glykoseoksidase i rekombinante systemer.
DE69514342D1 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
ES2087056T3 (es) 2-pirimidinaminas sustituidas en las posiciones 4, 5 y 6.
YU31891A (sh) Vektori i jedinjenja za ekspresiju mutanata glikozilovanja humanog proteina c
DE69033756T2 (de) Gene, die für MACIF Proteine kodieren, Expressionsvektoren mit diesem Genen, und Transformantenzellen mit diesem Proteinen
ATE59777T1 (de) Therapeutische zusammenstellungen auf basis von 3-alkoxyflavonen und derivate von 3-alkoxyflavonen.
DE3862073D1 (de) Tetramethyl-cis-diaza-bicyclo(4.2.0.)oktan-3,5-dion-derivate mit differentiationsinduzierender aktivitaet.
ITRM930343A0 (it) Proteine ricombinanti, vettori per l'espressione e loro usi.
FI950779A0 (fi) Homepromoottorit, jotka ovat aktiivisia glukoosin läsnäollessa

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN NOVEMBER 2002